Michelle received her BSc in Molecular and Cell Biology from the University of Connecticut during which she completed undergraduate research in a structural/microbiology lab. Following her undergraduate studies, she gained valuable experience at Arvinas Inc. in the Biophysics Department, where she worked on cancer and neurodegenerative disease targets. Currently, Michelle is a second-year PhD student in the Department of Molecular Pharmacology and Therapeutics. In the Vasan Lab, her research centers on investigating p110α degradation as a potential therapeutic strategy for PIK3CA-mutant breast cancer.